SPOKANE, Wash. – The FDA has approved a twice-yearly injection for HIV prevention following a groundbreaking clinical trial. Years before the approval, Dr. Rachel Safran was part of an original clinical trial on the drug.
While those clinical trials were focused on using Lenacapavir as a treatment for HIV, Safran said that the information collected, including dosage and frequency, was used in following clinical trials that led to the FDA approval of Lenacapavir as HIV prevention medication.
While the trial was being conducted, Safran said many people, including the elderly, volunteered…